CollPlant Holdings Ltd., a regenerative medicine company, focuses on developing and commercializing tissue repair products for three-dimensional (3D) bio-printing of tissues and organs, orthobiologics, and advanced wound care markets in the United States, Canada, and Europe. Its products are based on recombinant type I human collagen (rhCollagen) that is produced with its proprietary plant based genetic engineering technology. The company's products include Vergenix STR, a soft tissue repair matrix intended for treatment of tendinopathy; Vergenix FG, a wound-filling flowable gel for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds; and BioInks for 3D printing of tissues and organs. CollPlant Holdings Ltd. and is headquartered in Ness Ziona, Israel.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Surgical appliances & supplies
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CLGN
CUSIPN/A
Phone972-73-232-5600
Debt
Debt-to-Equity RatioN/A
Current Ratio3.06
Quick Ratio2.88
Price-To-Earnings
Trailing P/E Ratio-2.28
Forward P/E Ratio-1.76
P/E GrowthN/A
Sales & Book Value
Annual Sales$480,000.00
Price / Sales36.69
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)($2.26)
Net Income$-6,020,000.00
Net Margins-552.97%
Return on Equity-78.34%
Return on Assets-39.40%
Miscellaneous
Employees29
Outstanding Shares3,420,000
Market Cap$17.46 million
COLLPLANT HOLDI/S (NASDAQ:CLGN) Frequently Asked Questions
What is COLLPLANT HOLDI/S's stock symbol?
COLLPLANT HOLDI/S trades on the NASDAQ under the ticker symbol "CLGN."
When is COLLPLANT HOLDI/S's next earnings date?
Who are some of COLLPLANT HOLDI/S's key competitors?
Who are COLLPLANT HOLDI/S's key executives?
COLLPLANT HOLDI/S's management team includes the folowing people:
- Mr. Yehiel Tal, Chief Exec. Officer (Age 66)
- Prof. Oded Shoseyov, Founder and Chief Scientist Officer (Age 62)
- Mr. Eran Rotem, Deputy CEO & CFO (Age 50)
- Dr. Philippe David Bensimon, VP of Regulation Affairs and Quality Assurance (Age 53)
- Dr. Nadav Orr, VP of R&D (Age 61)
When did COLLPLANT HOLDI/S IPO?
(CLGN) raised $22 million in an initial public offering on Friday, December 9th 2016. The company issued 3,500,000 shares at $6.23 per share. Ladenburg Thalmann served as the underwriter for the IPO and Roth Capital Partners was co-manager.
How do I buy shares of COLLPLANT HOLDI/S?
Shares of CLGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is COLLPLANT HOLDI/S's stock price today?
One share of CLGN stock can currently be purchased for approximately $5.15.
How big of a company is COLLPLANT HOLDI/S?
COLLPLANT HOLDI/S has a market capitalization of $17.46 million and generates $480,000.00 in revenue each year. The company earns $-6,020,000.00 in net income (profit) each year or ($2.26) on an earnings per share basis. COLLPLANT HOLDI/S employs 29 workers across the globe.
What is COLLPLANT HOLDI/S's official website?
How can I contact COLLPLANT HOLDI/S?
COLLPLANT HOLDI/S's mailing address is 3 SAPIR ST. WEIZMANN SCIENCE PARK P.O.B. 4132, NESS-ZIONA L3, 74140. The company can be reached via phone at 972-73-232-5600 or via email at [email protected]
MarketBeat Community Rating for COLLPLANT HOLDI/S (NASDAQ CLGN)
MarketBeat's community ratings are surveys of what our community members think about COLLPLANT HOLDI/S and other stocks. Vote "Outperform" if you believe CLGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CLGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
